Brokerage firm Janney Capital Downgrades its rating on BIO-TECHNE Corp(TECH). The shares have been rated Neutral. The rating by the stock financial advisor at Janney Capital was issued on Mar 27, 2017 in a research report to their Investors and Clients.
In a different note, Citigroup said it Initiates Coverage On BIO-TECHNE Corp, according to a research note issued on Feb 9, 2017. In the research note, the firm Announces the price-target to $115 per share. The shares have been rated ‘Buy’ by the firm. Deutsche Bank said it Initiates Coverage On BIO-TECHNE Corp, according to a research note issued on Jan 18, 2017. In the research note, the firm Announces the price-target to $115 per share. The shares have been rated ‘Buy’ by the firm.
BIO-TECHNE Corp (TECH) made into the market gainers list on Fridays trading session with the shares advancing 0.31% or 0.32 points. Due to strong positive momentum, the stock ended at $103.82, which is also near the day’s high of $104.33. The stock began the session at $103.58 and the volume stood at 2,01,240 shares. The 52-week high of the shares is $117.42 and the 52 week low is $91.45. The company has a current market capitalization of $3,874 M and it has 3,73,11,809 shares in outstanding.
BIO-TECHNE Corp(TECH) last announced its earnings results on Feb 7, 2017 for Fiscal Year 2017 and Q2.Company reported revenue of $131.807M. Analysts had an estimated revenue of $134.010M. Earnings per share were $0.81. Analysts had estimated an EPS of $0.85.
Several Insider Transactions has been reported to the SEC. On Dec 13, 2016, Roger C Lucas (director) sold 100 shares at $108.93 per share price.Also, On Dec 1, 2016, Karen A Holbrook (director) sold 1,000 shares at $106.73 per share price.On Sep 12, 2016, Kevin S Gould (SVP Clinical Controls) sold 524 shares at $110.50 per share price, according to the Form-4 filing with the securities and exchange commission.
Bio-Techne Corporation (Bio-Techne) formerly Techne Corporation develops manufactures and sells biotechnology reagents instruments and clinical diagnostic products around the world. The Company has three business segments: the Biotechnology Clinical Controls and Protein Platforms divisions. The Biotechnology segment develops manufactures and sells biotechnology research and diagnostic products around the world. The Clinical Controls segment develops and manufactures controls and calibrators for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. Bio-Techne is engaged in providing specialized proteins including cytokines and growth factors antibodies related immunoassays biologically active small molecules and other reagents to the research diagnostics and clinical controls markets.